In this webinar, you’ll get an in-depth look at a case study of a helper-dependent adenovirus (HDAd) process from bench scale and optimization, to a successful scale-up and tech transfer using adherent culture.
Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective manufacturing processes are crucial. Yet, the complexity of scaling viral vector processes to commercial levels and the absence of standardized approaches pose significant challenges for therapy development timelines and productivity. Choosing the right production platform is essential for achieving commercial timelines and managing manufacturing costs.
In this webinar, you’ll get an in-depth look at a case study of a helper-dependent adenovirus (HDAd) process from bench scale and optimization, to a successful scale-up and tech transfer using adherent culture.
Join the webinar to learn how to:
- Achieve versatility with a scalable, single-use end-to-end platform
- Optimize small-scale expression systems into a scalable process
Offered Free by: Cytiva
See All Resources from: Cytiva
